Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand
Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.
Related Episodes
Continue listening to more episodes from FierceBiotech Radio.
